Gastroesophageal Reflux Disease (GERD) Market Size & Share, by Drug Type (Antacids, Proton Pump Inhibitors, H2 Receptor Blocker, Pro Kinetic Agents, Dopamine Receptor Antagonist, EndoCinch, Stretta, EsophyX, Transoral Incisionless, Fundoplication); Route of Administration (Oral, Parental); Distribution Channel (Hospital, Online, Retail); End-user (Hospital, Homecare, Specialty Clinics) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2035

  • Report ID: 5075
  • Published Date: Jun 26, 2023
  • Report Format: PDF, PPT

Companies Dominating the Gastroesophageal Reflux Disease (GERD) Landscape

    • AstraZeneca PLC
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Eisai Co., Ltd.
    • GSK plc.
    • Takeda Pharmaceutical Company Limited.
    • Ironwood Pharmaceuticals, Inc.
    • Johnson & Johnson Services, Inc.
    • SFJ Pharmaceuticals
    • Sebela Pharmaceuticals
    • Phathom Pharmaceuticals, Inc.
    • Camber Pharmaceuticals, Inc.

Browse Key Market Insights with Data Illustration:


In The News

  • AstraZeneca PLC has successfully signed the global license agreement with KYM Biosciences Inc. for the development of CMG901, an antibody-drug conjugate (ADC) targeting Claudin 18.2, a promising therapeutic target in gastric cancers.
  • Eisai Co., Ltd. and Bliss Biopharmaceutical Co., Ltd. have joined hands to develop BB-1701, an antibody-drug conjugate (ADC). This new drug is expected to have anti-tumor effects on breast, lung, and other solid tumors.

Author Credits:  Radhika Gupta, Shivam Bhutani

  • Report ID: 5075
  • Published Date: Jun 26, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Higher consumption of processed food, increase in digestive issues, and problems caused by contaminated food are the few factors likely to propel the market growth.

The market size of solar updraft towers is anticipated to attain a CAGR of ~2% over the forecast period, i.e., 2023 – 2035.

The major players in the market are AstraZeneca PLC, Eisai Co., Ltd., GSK plc., Takeda Pharmaceutical Company Limited., Ironwood Pharmaceuticals, Inc., Johnson & Johnson Services, Inc., SFJ Pharmaceuticals, Sebela Pharmaceuticals, Phathom Pharmaceuticals, Inc., Camber Pharmaceuticals, Inc., and other key players.

The company profiles are selected based on the revenues generated from the product segment, the geographical presence of the company which determines the revenue generating capacity as well as the new products being launched into the market by the company.

The market is segmented by drug type, route of administration, distribution channel, end-user, and by region.

The hospital segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.

The high costs of the treatment along with the unavailability of a professional and skilled workforce and the lack of awareness regarding the disease are estimated to be the growth hindering factors for the market expansion.

The market in the North American region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.
Inquiry Before Buying Request Free Sample

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying